REG - Cambridge Cognition - Result of General Meeting

Cambridge Cognition HoldingsAnnouncement

09/03/2020 12:50

RNS Number : 4653F
  
Cambridge Cognition Holdings PLC
  
09 March 2020
  
 

Cambridge Cognition Holdings Plc
 
("Cambridge Cognition" or the "Company")


Result of General Meeting
 
Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, is pleased to announce that all of the Resolutions proposed at the General Meeting held at its offices today to approve the proposed Placing and Subscription of up to 7,000,000 New Ordinary Shares and other related matters were duly passed.
Full details of the Resolutions were set out in the Circular published by the Company on 19 February 2020. The Circular is available for inspection in electronic form on the Company's website, www.cambridgecognititon.com. 
 
Total Voting Rights
 
Further to Admission, the Company's issued Ordinary Share capital will consist of 31,170,093 Ordinary Shares of 1 pence each, with voting rights. The Company does not hold any shares in Treasury.
Therefore the total number of voting rights is 31,170,093 and this figure may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement have the meanings ascribed to them in the circular to shareholders dated 19 February 2020 unless otherwise defined.
 
Enquiries
 




Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer 
Nick Walters, Chief Financial Officer


 
Tel: 01223 810 700
press@camcog.com




finnCap Ltd (NOMAD and Joint Broker)
Geoff Nash / Simon Hicks / Teddy Whiley
Alice Lane/Manasa Patil


Tel: 020 7220 0500
(Corporate Finance)
(ECM)




Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant


Tel: 020 3903 7715
 




IFC Advisory Ltd (Financial PR and IR)
Tim Metcalfe / Graham Herring / Zach Cohen


Tel: 020 3934 6630
 






About Cambridge Cognition


Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
 
For further information visit www.cambridgecognition.com
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ROMFLFSFVIIAIII